



Global COVID-19 Clinical Platform

NOVEL CORONAVIRUS (COVID-19) - RAPID VERSION

DESIGN OF THIS CASE RECORD FORM (CRF)

This CRF has 3 modules:

Module 1 to be completed on the first day of admission to the health centre.

Module 2 to be completed on first day of admission to ICU or high dependency unit. Module 2 should also be completed daily for as many days as resources allow. Continue to follow-up patients who transfer between wards.

Module 3 to be completed at discharge or death.

GENERAL GUIDANCE

- The CRF is designed to collect data obtained through examination, interview and review of hospital notes. Data may be collected retrospectively if the patient is enrolled after the admission date.
- Participant Identification Numbers consist of a site code and a participant number.
 You can obtain a site code and register on the data management system by contacting EDCARN@who.int
 Participant numbers should be assigned sequentially for each site beginning with 00001. In the case of a single site recruiting participants on different wards, or where it is otherwise difficult to assign sequential numbers, you can assign numbers in blocks or incorporate alpha characters. E.g. Ward X will assign numbers from 00001 or A0001 onwards and Ward Y will assign numbers from 50001 or B0001 onwards. Enter the Participant Identification Number at the top of every page.
- Data are entered to the central electronic REDCap database at https://ncov.medsci.ox.ac.uk or to your site/network's independent database. Printed paper CRFs may be used and the data can be typed into the electronic database afterwards.
- Complete every section. Questions marked "If yes,..." should be left blank when they do not apply (i.e. when the answer is not yes).
- Selections with square boxes (□) are single selection answers (choose one answer only).
- Selections with circular boxes (O) are multiple selection answers (choose all that apply).
- Mark 'Unknown' for any data that are not available or unknown.
- Avoid recording data outside of the dedicated areas.
- If using paper CRFs, we recommend writing clearly in ink, using BLOCK-CAPITAL LETTERS.
- Place an (X) in the boxes to mark the answer. To make corrections, strike through (-----) the data you wish to delete and write the correct data above it. Please initial and date all corrections.
- Please keep all of the sheets for a single participant together e.g. with a staple or participant-unique folder.
- Please transfer all paper CRF data to the electronic database. All paper CRFs can be stored by the institution responsible for them. All data should be transferred to the secure electronic database.
- Please enter data on the electronic data capture system at https://ncov.medsci.ox.ac.uk. If your site would like to collect data independently, we can support the establishment of locally hosted databases.
- Please contact us at <u>EDCARN@who.int</u> If we can help with databases, if you have comments and to let us know
 that you are using the forms.





PARTICIPANT ID I	- 11	- 11	Ш	11		- 11	11	11

MODULE1: complete on admission/enrolment

Site name Country										
Date of enrolment [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]										
CLINICAL INCLUSION CRITERIA										
Proven or suspected infection with	Proven or suspected infection with pathogen of Public Health Interest □Yes □No									
One or more A history	ore A history of self-reported feverishness or measured fever of ≥ 38₀C □Yes □No									
of these Cough			□Yes □No							
during this Dyspnoe	ea (shortness of breath) OR Tachypnoea*	□Yes □No							
illness Clinical suspicion of ARI despite not meeting criteria above □Yes □No										
* respiratory rate ≥50 breaths/min for	<1 year; ≥40 for 1-4 year	s; ≥30 for 5-12 years; ≥20 for ≥13 years								
DEMOGRAPHICS										
		of birth [_D_][_D_]/[_M_][_M_]/[_Y_][_Y_][_Y_]							
If date of birth is unknown, records	•	<u> </u>								
Healthcare Worker? □Yes □No	D □Unknown La l	ooratory Worker? □Yes □No □Unl	known							
Pregnant? □Yes □No □Unkn	own □N/A If y €	es: Gestational weeks assessment [_][] weeks							
DATE OF ONOFT AND ADMICO	ION WITH CLONE /5:		incinu)							
	•	st available data at presentation/admi	SSION)							
Symptom onset (date of first/earliest symptom) [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]										
Admission date at this facility [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] Temperature [][].[]°C										
		[]beats/min								
Respiratory rate [][]breath		nmHg Severe dehydration □Yes								
Sternal capillary refill time >2se	,	•	LINO LIGHKHOWH							
Oxygen saturation: [][]%			P U (circle one)							
Glasgow Coma Score (GCS /15)		Inutrition □Yes □No □Unknown	(onoic one)							
Mid-upper arm circumference [_			ght : [][]kg							
			3 1 1 1 1 1 1							
CO-MORBIDITIES (existing prior	to admission) (Unk =	Jnknown)								
Chronic cardiac disease (not hypertension)	□Yes □No □Un	k Diabetes	□Yes □No □Unk							
Hypertension	□Yes □No □Un	k Current smoking	□Yes □No □Unk							
Chronic pulmonary disease	□Yes □No □Un	k Tuberculosis	□Yes □No □Unk							
Asthma	□Yes □No □Un	k Asplenia	□Yes □No □Unk							
Chronic kidney disease	□Yes □No □Un	k Malignant neoplasm	□Yes □No □Unk							
Chronic liver disease	□Yes □No □Un	<u>k</u> Other	□Yes □No □Unk							
Chronic neurological disorder	□Yes □No □Un	k If yes, specify:								
HIV	□Yes-on ART □	es-not on ART □No □Unknow	n							
	IEDIOATION W		41							
PRE-ADMISSION & CHRONIC N	IEDICATION Wer	e any of the following taken within 1	4 days of admission?							
Angiotensin converting enzyme in	•									
Angiotensin II receptor blockers (A	Angiotensin II receptor blockers (ARBs)? □Yes □No □Unknown									
Non-steroidal anti-inflammatory (NSAID)? □Yes □No □Unknown										





Organization ISARIC		PARTIC	IPANTIDITITI	<u> </u>		<u> </u>		
SIGNS AND SYMPTOR	MS ON ADMISSION (Unk	= Unkn	own)					
History of fever	□Yes □No □Ur	nk L	ower chest wall indrawing	□Yes	□No	□Unk		
Cough	□Yes □No □Ur	nk l	Headache.	□Yes	□No	□Unk		
with sputum produc	tion □Yes □No □Ur	nk A	Altered consciousness/confu	usion □Yes	□No	□Unk		
with haemoptysis	□Yes □No □Ur	nk S	Seizures	□Yes	□No	□Unk		
Sore throat	□Yes □No □Ur	nk A	Abdominal pain	□Yes	□No	□Unk		
Runny nose (rhinorrhoea)	. □Yes □No □Ur	nk \	/omiting / Nausea	□Yes	□No	□Unk		
Wheezing	□Yes □No □Ur	nk [Diarrhoea	□Yes	□No	□Unk		
Chest pain.	□Yes □No □Ur	nk (Conjunctivitis	□Yes	□No	□Unk		
Muscle aches (myalgia)	□Yes □No □Ur	nk S	Skin rash	□Yes	□No	□Unk		
Joint pain (arthralgia).	□Yes □No □Ur	nk S	Skin ulcers	□Yes	□No	□Unk		
Fatigue / Malaise	□Yes □No □Ur	nk L	ymphadenopathy	□Yes	□No	□Unk		
Shortness of breath .	□Yes □No □Ur	nk E	Bleeding (Haemorrhage).	□Yes	□No	□Unk		
Inability to walk	□Yes □No □Ur	nk	If bleeding: specify site(s): _					
Other □Yes □No □Un	k If yes, specify:							
	patient CURRENTLY rece							
Oral/orogastric fluids? Yes No Unknown Intravenous fluids? Yes No Unknown Antiviral? Yes No Unknown If yes: ORibavirin OLopinavir/Ritonavir ONeuraminidase inhibitor Olnterferon alpha Olnterferon beta OOther, specify:								
,) support? □Yes □No .TS ON ADMISSION (*reco		-	□Yes □No □	Unknowr	<u>1</u>		
	·	Not	1	1		Not		
Parameter	Value*	done	Parameter	Value*		done		
Haemoglobin (g/L)			Creatinine (µmol/L)					
WBC count (x109/L)			Sodium (mEq/L)					
Haematocrit (%)			Potassium (mEq/L)					
Platelets (x10 ₉ /L)			Procalcitonin (ng/mL)					
APTT/APTR			CRP (mg/L)					
PT (seconds)			LDH (U/L)					
INR			Creatine kinase (U/L)					
ALT/SGPT (U/L)			Troponin (ng/mL)		_			
Total bilirubin (µmol/L)			ESR (mm/hr)		_			
AST/SGOT (U/L)			D-dimer (mg/L)		_			
Urea (BUN) (mmol/L)			Ferritin (ng/mL)		_			
Lactate (mmol/L)		П	II 6 (ng/ml)					





PARTICIPANT ID I	11	- 11	- 11	11	I I	11	11	11
I ANTICII ANTI ID I			1.1	1.1	1 1			1.1

MODULE 2: follow-up (frequency of completion determined by available resources)

Date of follow up [_D_][
VITAL SIGNS (record i												
Temperature [][]							_	-				
BP [] [] [sys	tolic)	[][_][]((diasto	olic) mr	nHg Sever	e dehydra	tion □Ye	es □No	□Unk	nowr	า
Sternal capillary refill	time	>2secor	nds 🗆	Yes	□No	□Unknown	GCS/1	5 [][_]			
Oxygen saturation [_][_][]%	on 🗆 r	oom a	air 🗆 ox	ygen therapy	□Unknown	<u> </u>	A V P	U (cire	cle d	one)
DAILY CLINICAL FEAT	TUR	ES (Unk	= Unkno	own)								
Cough	Cough											
and sputum product	ion	□Yes	□No	□Ur		omiting / Naus	sea		□Yes	□No		Unk
Sore throat Chest pain		□Yes □Yes	□No □No	□Ur □Ur		Diarrhoea Conjunctivitis			□Yes □Yes	□No □No		Unk Unk
Shortness of breath		□Yes	□No	□Ur		Jonjunctivitis Myalgia			□Yes			Unk
Confusion		□Yes	□No	□Ur	nk (Other, specify:_			□Yes	□No		Unk
LABORATORY RESUL	.TS (*record u	nits if d	lifferei	nt from	those listed)						
Parameter	Val	ue*			Not done	Parameter		Value*				Not done
Haemoglobin (g/L)						Creatinine (µ	mol/L)					
WBC count (x109/L)						Sodium (mEd	q/L)					
Haematocrit (%)						Potassium (n	nEq/L)					
Platelets (x109/L)						Procalcitonin	n (ng/mL)					
APTT/APTR						CRP (mg/L)						
PT (seconds)						LDH (U/L)						
INR						Creatine kina	ase (U/L)					
ALT/SGPT (U/L)						Troponin (ng/r						
Total bilirubin (µmol/L)						ESR (mm/hr)						
AST/SGOT (U/L)						D-dimer (mg/L	_)					
Urea (BUN) (mmol/L)						Ferritin (ng/ml	_)					
Lactate (mmol/L)						IL-6 (pg/mL)						
MEDICATION Is the	patie	ent CURI	RENTL	Y rec	eiving a	any of the follo	owing?					
Oral/orogastric fluids?	ΥC	es □No [□ Unkno	wn I	ntrave	nous fluids? 🗆	∃Yes □No	Unknov	/n			
Antiviral? □Yes □No			_			-	navir O Ne	uraminida	ase inhibi	tor		
OInterferon alpha OIn				-	-							
Corticosteroid? □Yes							enous O In	haled				
If yes, please provide agent and maximum daily dose: Antibiotic? □Yes □No □Unknown Antifungal agent? □Yes □No □Unknown												
Antibiotic?			L	16					iknown			
Antimalarial agent? [Experimental agent?				_		=						
Non-steroidal anti-infla						=						
			-]No □Unk	nown				
Angiotensin converting enzyme inhibitors (ACE inhibitors) □Yes □No □Unknown Angiotensin II receptor blockers (ARBs) □Yes □No □Unknown												
SUPPORTIVE CARE Is the patient CURRENTLY receiving any of the following?												
ICU or High Dependency Unit admission? □Yes □No □Unknown												
Date of ICU/HDU admission [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] □Unknown												
ICU/HDU discharge date [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] □Not discharged yet □Unknown												
Oxygen therapy? Yes No Unknown If yes, complete all below:												
O₂ flow volume: □1-5 L/min □6-10 L/min □11-15 L/min □>15 L/min □Unknown												
Source of oxygen: Piped Cylinder Concentrator Unknown Interface: Nasal pronge UHE pasal cappula UMask UMask with reservoir UCRAR/NIV mask Ullakeours												
Interface: □Nasal prongs □HF nasal cannula □Mask □Mask with reservoir □CPAP/NIV mask □Unknown												
Non-invasive ventilation? (e.g. BIPAP, CPAP)												
•	Invasive ventilation (Any)? □Yes □No □Unknown Inotropes/vasopressors? □Yes □No □Unknown Extracorporeal (ECMO) support? □Yes □No □Unknown Prone position? □Yes □No □Unknown											
-	Renal replacement therapy (RRT) or dialysis? □Yes □No □Unknown											





PARTICIPANT ID	1 11	11	11	11	1 1	11	11	11	
171111111111111111111111111111111111111									

MODULE 3: complete at discharge/death

DIAGNOSTIC/PATHOGEN TE	ESTING							
Chest X-Ray /CT performed?	? □Yes □No □Unknown If Y	es: infiltrates present? □	Yes □No □Unknown					
<u> </u>	during this illness episode?	· · · · · · · · · · · · · · · · · · ·						
	□Negative □Not done If po s							
	Negative □Not done If positive							
	en: □Positive □Negative □Not							
	: □Positive □Negative □Not dor							
_	health interest detected: If ye	• • • •						
I	sitive □Negative □Not done No							
HIV: □Positive □Negative			silive Livegalive Liver dolle					
	ne during hospitalisation did t	the nationt experience:						
Shock	☐Yes ☐No ☐Unknown	Bacteraemia	□Yes □No □Unknown					
Seizure	□Yes □No □Unknown	Bleeding	☐Yes ☐No ☐Unknown					
Meningitis/Encephalitis	□Yes □No □Unknown	Endocarditis	□Yes □No □Unknown					
Anaemia	□Yes □No □Unknown	Myocarditis/Pericarditis	□Yes □No □Unknown					
Cardiac arrhythmia	□Yes □No □Unknown	Acute renal injury	□Yes □No □Unknown					
Cardiac arrest	□Yes □No □Unknown	Pancreatitis	□Yes □No □Unknown					
Pneumonia	□Yes □No □Unknown	Liver dysfunction	□Yes □No □Unknown					
Bronchiolitis	□Yes □No □Unknown	Cardiomyopathy	□Yes □No □Unknown					
Acute Respiratory Distress	□Yes □No □Unknown	Other	□Yes □No □Unknown					
Syndrome		If Yes, specify						
MEDICATION: While hospital	lised or at discharge, were an	y of the following adminis	tered?					
Oral/orogastric fluids? □Yes	□No □Unknown Intraveno	us fluids? □Yes □No □U	nknown					
Antiviral? □Yes □No □Unl	known If yes: ORibavirin OLo	opinavir/Ritonavir O Neuram	ninidase inhibitor					
	OInterferon beta OOther, spec							
	nknown If yes, specify:							
Corticosteroid? □Yes □No	□Unknown If yes, route: ○ C	Oral OIntravenous OInhale	d					
If yes, specify agent and ma	aximum daily dose:							
	No □Unknown If yes, specify							
	□No □Unknown If yes, speci							
_	□No □Unknown If yes , spec							
_	ory (NSAID)	-						
	time during hospitalisation,							
		·						
ICU or High Dependency Unit admission? □Yes □No □ Unknown If yes, total duration:days								
Date of ICU admissi	ion:[_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] □N/A						
Oxygen therapy? Yes No Unknown If yes, complete all: Total duration:days								
O ₂ flow volume: O1-5 L/min O6-10 L/min O11-15 L/min O>15 L/min								
Source of oxygen: OPiped OCylinder OConcentrator								
Interface: ONasal prongs OHF nasal cannula OMask OMask with reservoir OCPAP/NIV mask								
Non-invasive ventilation? (e.g. BIPAP, CPAP) Yes No Unknown If yes, total duration:days								
Invasive ventilation (Any)? Yes No Unknown If yes, total duration: days								
Extracorporeal (ECMO) support? Yes No Unknown If yes, total duration:days								
Prone position? □Yes □No □ Unknown If yes, total duration:days								
Renal replacement therapy (RRT) or dialysis? Yes No Unknown								
Inotropes/vasopressors? □Yes □No □Unknown If yes, total duration:days								
OUTCOME								
Outcome: Discharged alive	Outcome: □Discharged alive □Hospitalized □Transfer to other facility □Death □Palliative discharge □Unknown							
Outcome date: [D][D]/[I	M_][_M_]/[_2_][_0_][_Y_][_Y_]	□Unknown						
			as before illness. □Worse					
If Discharged alive: Ability to self-care at discharge versus before illness: □Same as before illness □Worse □Better □Llnknown								